Fosamax and Osteonecrosis of the Jaw: Causation and Risk in Medical Literature

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health to Occupational Exposure

The legacy of general health and science information has long provided a foundation for public understanding of medical risks and therapeutic benefits. Within this broad context, the dissemination of knowledge regarding prescription medications and their potential adverse effects has been a central concern. Historically, this discourse has focused on patient-oriented guidance, emphasizing informed consent and clinical vigilance. As the domain of mass production evolves, the focus necessarily shifts from the individual patient to the occupational environment. In manufacturing settings, the handling of pharmaceutical compounds introduces distinct exposure pathways that differ from prescribed therapeutic use. The transition from a general health framework to an occupational exposure concern requires acknowledging that workers involved in the production of medications may encounter these substances under conditions not accounted for in standard patient education. This pivot is particularly relevant when considering the risk profile of bisphosphonate medications, such as Fosamax, and the rare but serious condition of osteonecrosis of the jaw. While the legacy context addresses patient risk, the occupational lens must evaluate inhalation, dermal contact, and chronic low-level exposure during manufacturing processes. This shift in perspective underscores the need for targeted workplace safety protocols and exposure monitoring, moving beyond the patient-centric model to protect those who produce these therapies.

Bridging Patient and Occupational Risk

Understanding the medical evidence for Fosamax-associated osteonecrosis of the jaw (ONJ) is essential for both patients and workers. Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a recognized adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed necrotic bone in the maxillofacial region that can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation often involves pain, swelling, and non-healing extraction sockets. Diagnosis relies on clinical examination and imaging, with the identification of exposed bone persisting for more than eight weeks in the absence of radiation therapy to the jaws. The condition has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Mechanisms and Risk Factors for ONJ

The mechanistic pathways linking Fosamax to ONJ are not fully elucidated but are believed to involve the drug's potent inhibition of osteoclast activity. Bisphosphonates accumulate in bone, particularly in areas of high turnover such as the jaw, and suppress bone remodeling. This suppression can impair the ability of the jawbone to repair microdamage and respond to local infections or trauma, such as tooth extraction. Multiscale characterization of jawbone tissue has provided comprehensive information that helps understand jawbone-specific responses to bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). Additionally, the anti-angiogenic properties of bisphosphonates may contribute to reduced blood supply to the jawbone, further predisposing it to necrosis. Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Timeline and Causation Evidence

The timeline between exposure to Fosamax and documented harm varies. The time to onset of symptoms ranged from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In a cohort study among female patients treated for osteoporosis in the United Kingdom, ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). This indicates that while the relative risk increases with longer exposure, the absolute risk remains small. Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific warning under section 5.4 titled "Osteonecrosis of the Jaw" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This warning states that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and notes that it is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also advises discontinuation if severe symptoms develop and notes that most patients had relief of symptoms after stopping, though a subset had recurrence when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Additionally, the label for Fosamax Plus D includes a more detailed list of risk factors and notes that discontinuation of bisphosphonate treatment may reduce risk for patients requiring invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). These warnings provide healthcare providers and patients with information to assess and mitigate risk.

Causation Assessment and Clinical Implications

For affected patients, causation considerations involve evaluating the temporal relationship between Fosamax use and the development of ONJ, as well as the presence of other risk factors. The timeline data show that risk increases with duration of use, with a notable increase after 2-3 years (https://pubmed.ncbi.nlm.nih.gov/39400702/). However, ONJ can also occur in patients not taking bisphosphonates, and the condition is often associated with dental procedures or local infections (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Therefore, a thorough clinical assessment is necessary to determine the likely contribution of Fosamax in individual cases. The risk diminishes after discontinuation, suggesting that cessation of the drug may reduce further harm (https://pubmed.ncbi.nlm.nih.gov/39400702/). In summary, Fosamax is associated with an increased risk of ONJ, particularly with longer duration of use and in the presence of other risk factors such as invasive dental procedures. The prescribing information includes warnings about this risk, and patients should be counseled on maintaining good oral hygiene and avoiding elective invasive dental procedures during treatment. For those who develop ONJ, discontinuation of Fosamax may lead to symptom relief, though recurrence is possible upon rechallenge.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how does it work?

Fosamax (alendronate) is a bisphosphonate medication used to treat and prevent osteoporosis by inhibiting bone resorption, thereby increasing bone mass and reducing fracture incidence (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What is osteonecrosis of the jaw (ONJ) and how is it linked to Fosamax?

ONJ is a condition characterized by exposed necrotic bone in the jaw, often associated with tooth extraction or local infection. It has been reported in patients taking bisphosphonates like Fosamax, likely due to suppression of bone remodeling and reduced blood supply (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and pre-existing dental disease. Duration of bisphosphonate use also increases risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How long does it take for ONJ to develop after starting Fosamax?

Onset can range from one day to several months after starting the drug. Risk increases with longer use, with a threefold increase after 2-3 years and eightfold after 10 years compared to past use (https://pubmed.ncbi.nlm.nih.gov/39400702/).

Can stopping Fosamax reduce the risk of ONJ?

Yes, the risk of ONJ diminishes after discontinuation. For patients requiring invasive dental procedures, temporary discontinuation may reduce risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.